The Therapeutic Goods Administration (TGA) is working with pharmaceuticals and medical organisations to reduce the impact of the global shortage of the two diabetic medicines: Ozempic (semaglutide) and Trulicity (dulaglutide).
NB: There will be no further supplies of Ozempic available in Australia and access to Trulicity is expected to be very limited until the end of March 2023.
Please help disseminate this information out to patients to allow time to access alternative treatments. TGA has published two webpages (links below) providing practical information and advice about these shortages including a link to new clinical guidelines from RACGP:
• Ozempic (semaglutide) shortage web page
• Trulicity (dulaglutide) shortage web page
If you have any questions, please contact the Medicine Shortages Section on +612 6289 4646 [email protected].